{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:27:29Z","timestamp":1787768849470,"version":"build-2784847793"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prro.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:32:02Z","timestamp":1749065522000},"page":"578-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5725-9959","authenticated-orcid":false,"given":"Svenja","family":"Hering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hofmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Mansoorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa da Silva","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.05.006_bib0001","series-title":"Abeloff\u2019s Clinical Oncology","first-page":"764","article-title":"Lung metastases","author":"Ripley","year":"2013"},{"key":"10.1016\/j.prro.2025.05.006_bib0002","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0003","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: A randomized, multi-institution, phase 2 trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0004","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): The trans Tasman Radiation Oncology Group 13.01 phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2021.05.116","article-title":"Ten-year experience in implementing single-fraction lung SBRT for medically inoperable early stage lung cancer","volume":"111","author":"Videtic","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cllc.2013.06.006","article-title":"Clinical outcomes of single dose stereotactic radiotherapy for lung metastases","volume":"14","author":"Osti","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.prro.2025.05.006_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7785\/tcrt.2012.500355","article-title":"Outcomes of single fraction Stereotactic Ablative Radiotherapy for lung metastases","volume":"13","author":"Filippi","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2025.05.006_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00066-007-1724-z","article-title":"Stereotactic single-dose radiotherapy of lung metastases","volume":"183","author":"Hof","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2025.05.006_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/JTO.0b013e318279155f","article-title":"Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States","volume":"8","author":"Daly","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0010","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.adro.2020.06.011","article-title":"Single-fraction stereotactic body radiation therapy: A paradigm during the coronavirus disease 2019 (COVID-19) pandemic and beyond?","volume":"5","author":"Ng","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0011","first-page":"16","article-title":"A review of the role of MRI in diagnosis and treatment of early stage lung cancer","volume":"24","author":"Sim","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.617681","article-title":"Initial clinical experience of MR-guided radiotherapy for non-small cell lung cancer","volume":"11","author":"Crockett","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-019-1308-y","article-title":"MR-guidance in clinical reality: Current treatment challenges and future perspectives","volume":"14","author":"Corradini","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.radonc.2021.03.025","article-title":"ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology","volume":"159","author":"Corradini","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semradonc.2023.10.007","article-title":"Exploring the advantages and challenges of MR-guided radiotherapy in non-small-cell lung cancer: Who are the optimal candidates?","volume":"34","author":"Wu","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.radonc.2019.02.019","article-title":"Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy","volume":"135","author":"Steiner","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170522","article-title":"Initial clinical observations of intra- and interfractional motion variation in MR-guided lung SBRT","volume":"91","author":"Thomas","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.05.006_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phro.2020.05.002","article-title":"Delivery of magnetic resonance-guided single-fraction stereotactic lung radiotherapy","volume":"14","author":"Finazzi","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0019","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/acm2.13016","article-title":"Direct tumor visual feedback during free breathing in 0.35T MRgRT","volume":"21","author":"Kim","year":"2020","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-022-02021-6","article-title":"Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: Liver, lung, abdominal lymph nodes, pancreas and prostate","volume":"17","author":"Nierer","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-022-02011-8","article-title":"MR-guided radiotherapy in node-positive non-small cell lung cancer and severely limited pulmonary reserve: A report proposing a new clinical pathway for the management of high-risk patients","volume":"17","author":"Eze","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0022","article-title":"The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours","volume":"45","author":"Hering","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: What we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0024","first-page":"98","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","author":"Kl\u00fcter","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: Magnetic resonance\u2013guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0026","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0027","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2025.05.006_bib0028","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: A systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0029","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.prro.2025.05.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109823","article-title":"Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy","volume":"187","author":"Tekatli","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.radonc.2019.10.013","article-title":"Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors","volume":"144","author":"Finazzi","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13014-023-02330-4","article-title":"Deep learning based automatic segmentation of organs-at-risk for 0.35 T MRgRT of lung tumors","volume":"18","author":"Ribeiro","year":"2023","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.prro.2025.05.006_bib0033","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2018.12.041","article-title":"Single fraction SBRT for early stage lung cancer\u2014less is more?","volume":"103","author":"Siva","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818794936","article-title":"Stereotactic radiotherapy for pulmonary oligometastases from colorectal cancer: A systematic review and meta-analysis","volume":"17","author":"Jingu","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2025.05.006_bib0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ijrobp.2015.04.004","article-title":"Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy","volume":"92","author":"Binkley","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0036","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ijrobp.2017.02.093","article-title":"Stereotactic ablative radiation therapy for pulmonary metastases: Histology, dose, and indication matter","volume":"98","author":"Helou","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0037","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaoncol.2023.3495","article-title":"Individualized stereotactic ablative radiotherapy for lung tumors: The iSABR phase 2 nonrandomized controlled trial","volume":"9","author":"Gensheimer","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0038","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1634\/theoncologist.2016-0324","article-title":"Pulmonary function changes after radiotherapy for lung or esophageal cancer: A systematic review focusing on dose-volume parameters","volume":"22","author":"Niezink","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.prro.2025.05.006_bib0039","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ijrobp.2013.12.050","article-title":"No clinically significant changes in pulmonary function following stereotactic body radiation therapy (SBRT) for early stage peripheral non-small cell lung cancer: An analysis of RTOG 0236","volume":"88","author":"Stanic","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.674731","article-title":"Lung function after stereotactic body radiation therapy for early-stage non-small cell lung cancer, changes and predictive markers","volume":"11","author":"Berg","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0041","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/JTO.0b013e3181a99ff6","article-title":"Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients","volume":"4","author":"Stephans","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0042","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijrobp.2007.12.051","article-title":"Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer","volume":"72","author":"Henderson","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0043","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: A systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.05.006_bib0044","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/cns.12.14","article-title":"Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas","volume":"1","author":"Yovino","year":"2012","journal-title":"CNS Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0045","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.139.10.3199","article-title":"Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes","volume":"139","author":"Sellins","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.prro.2025.05.006_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fimmu.2016.00020","article-title":"T cells and cancer: How metabolism shapes immunity","volume":"7","author":"Molon","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.prro.2025.05.006_bib0047","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.prro.2025.05.006_bib0048","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1172\/JCI108084","article-title":"A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients","volume":"56","author":"Stratton","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.prro.2025.05.006_bib0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/curroncol29010019","article-title":"Impact of pre-treatment NLR and other hematologic biomarkers on the outcomes of early-stage non-small-cell lung cancer treated with stereotactic body radiation therapy","volume":"29","author":"Aduquaye","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0050","first-page":"133","article-title":"Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point","volume":"28","author":"Kotha","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0051","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7150\/jca.21703","article-title":"Systemic inflammation biomarkers predict survival in patients of early stage non-small cell lung cancer treated with stereotactic ablative radiotherapy-\u2014A single center experience","volume":"9","author":"Luo","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.prro.2025.05.006_bib0052","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3747\/co.23.3051","article-title":"Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy","volume":"23","author":"Giuliani","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0053","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cllc.2015.07.007","article-title":"Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy","volume":"17","author":"Shaverdian","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.prro.2025.05.006_bib0054","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/JTO.0000000000000399","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer","volume":"10","author":"Cannon","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12885-023-10719-3","article-title":"Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.05.006_bib0056","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2019.01.032","article-title":"Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"134","author":"Sebastian","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0057","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.prro.2025.05.006_bib0058","article-title":"The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: A systematic review and meta-analysis","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.prro.2025.05.006_bib0059","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.21037\/tlcr-23-7","article-title":"Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy","volume":"12","author":"Sung","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.prro.2025.05.006_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1039121","article-title":"The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"9","author":"Guven","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.prro.2025.05.006_bib0061","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41698-022-00267-7","article-title":"Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade","volume":"6","author":"Yoo","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.prro.2025.05.006_bib0062","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma\u2014The RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025001493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:53Z","timestamp":1761900233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025001493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1879850025001493"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.006","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Assessment of MR Guided Single-Fraction Stereotactic Ablative Radiation Therapy for Peripheral Lung Metastases: Dosimetric and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}